EZH2 and neoplasm: We also showed that the dual G9A/EZH2 inhibitor HKMTI-1–005 (19) powerfully modified accessible chromatin in a syngeneic HGSC model, accompanied by transcriptional upregulation of immune pathways and, critically, substantial modulation of the tumor immune microenvironment.